

Safety of Overnight Orthokeratology for Myopia

A Report by the American Academy of Ophthalmology

Woodford S. Van Meter, MD, David C. Musch, PhD, MPH, Deborah S. Jacobs, MD, Stephen C. Kaufman, MD, PhD, William J. Reinhart, MD, Ira J. Udell, MD

Objective: To review the published literature to evaluate the safety of overnight orthokeratology (OOK) for the treatment of myopia.

Methods: Repeated searches of peer-reviewed literature were conducted in PubMed (limited to the English language) and the Cochrane Central Register of Controlled Trials (no language limitations) for 2005, 2006, and 2007. The searches yielded 495 citations. The panel reviewed the abstracts of these articles and selected 79 articles of possible clinical relevance for review. Of these 79 full-text articles, 75 were determined to be relevant to the assessment objective.

Results: No studies were rated as having level I evidence. Two premarket applications to the Food and Drug Administration were rated as having level II evidence. There were 2 studies rated as having level II evidence. The main source of reports of adverse events associated with OOK was 38 case reports or noncomparative case series (level III evidence).

Conclusions: The prevalence and incidence of complications associated with OOK have not been determined. Complications, including more than 100 cases of infectious keratitis resulting from gram-positive and gram-negative bacteria and *Acanthamoeba*, have been described in case reports and case series representing observations in undefined populations of OOK users. Data collection was nonstandard. Risk factors for various complications cannot be determined. Because OOK puts patients at risk for vision-threatening complications they may not encounter otherwise, sufficiently large well-designed cohort or randomized controlled studies are needed to provide a more reliable measure of the risks of treatment and to identify risk factors for complications. Overnight orthokeratology for slowing the progression of myopia in children also needs well-designed and properly conducted controlled trials to investigate efficacy. Because of variations in orthokeratology practice, a wide margin of safety should be built into OOK regimens.

Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. *Ophthalmology* 2008;115:2301–2313 © 2008 by the American Academy of Ophthalmology.



The American Academy of Ophthalmology prepares Ophthalmic Technology Assessments to evaluate new and existing procedures, drugs, and diagnostic and screening tests. The goal of an Ophthalmic Technology Assessment is to evaluate the peer-reviewed scientific literature, to distill what is well established about the technology, and to help refine the important questions to be answered by future investigations. After appropriate review by all contributors, including legal counsel, assessments are submitted to the Academy's Board of Trustees for consideration as official Academy statements.

Background

Orthokeratology is the reduction, modification, or elimination of refractive anomalies by the programmed application

of contact lenses.¹ Although permanent changes frequently are desired, investigators generally agree that overnight orthokeratology (OOK) changes of the cornea are only temporary and that to maintain OOK changes, retainer lenses must be worn during the day or during sleep. Orthokeratology has generated both successful outcomes and concern over reported complications. The purpose of this review was to examine the safety of OOK so that those interested in the subject can make a rational assessment of the risks associated with the technique. This assessment does not provide a systematic review of the effectiveness of OOK.

There is worldwide interest in OOK as an alternative to refractive surgical procedures to treat myopia, particularly in young people. The attractiveness of reducing myopia without surgery at perhaps a lower price and using conventional methodology (contact lenses) has not been over-

looked by the world market. Children frequently present as candidates for OOK because of the parents' desire to prevent myopia progression and age contradictions to refractive surgery. Eye care providers who do not offer surgical options for refractive errors may offer OOK as an additional treatment option to their patients.

The prevalence of myopia is particularly high in certain ethnic populations. Myopia has been reported in 37% of 7560 children in Hong Kong age 5 to 16 years.² Myopia prevalence rates of 56% to 85% have been reported in teenagers³ and young adults⁴ in Singapore.

The popularity of various refractive surgical procedures, starting with radial keratotomy in 1980 and subsequently epikeratophakia, excimer laser photorefractive keratectomy and laser in situ keratomileusis, intrastromal corneal ring segments, and intracorneal and intraocular lens implantation demonstrates that many myopic patients are willing to undertake some degree of risk to reduce their dependence on eyeglasses or contact lenses. Although it has been suggested that orthokeratology can slow the progression of myopia in children, 2 controlled, prospective studies have demonstrated a lack of effect of conventional rigid gas-permeable (RGP) contact lenses on the progression of myopia, and it is generally agreed that OOK produces only a temporary effect.^{5,6} A pilot study of OOK for myopia control showed less increase in axial length in the OOK group compared with eyeglass wearers.⁷ However, this study used historical controls and there was no standardized protocol for fitting the contact lenses for OOK, possibly contributing to the somewhat unpredictable published results for individual children.

History

Multiple methods to eliminate myopia have been recorded historically. Unconfirmed stories suggest that in ancient China, some individuals slept with small weights or sand bags on their eyelids to reduce myopia.¹ In the 19th century, personal necessity prompted August Muller-Gladback, a German ophthalmologist with -14.00 diopters (D) of myopia, to grind corneal contact lenses for himself, and he coined the term *cornea lens*.⁸ Although the optics of his contact lenses were satisfactory, unfortunately, he could not wear the contact lenses for more than 30 minutes because of discomfort. In 1888, Eugene Kalt in Paris, France, used glass contact lenses to flatten the keratoconic cornea into a more normal shape.⁹

The first plastic corneal contact lens was designed by Kevin Tuohy in California in 1945⁸ and was fit flatter than the anterior corneal curvature (keratometric curvature or K) to encourage exchange of tears. It subsequently was noted that the flat fit of the contact lenses induced irregularities of the cornea surface in wearers, a fact borne out subsequently by the observations of multiple clinicians. Those using the contact lenses themselves reported that their vision was affected by the contact lenses even when they were not wearing them.

Optometrists fitting contact lenses in the 1950s observed similar flattening changes in the corneal curvature and refraction, which led them to note that myopia could be reduced by the type of fit of the contact lens on the cor-

nea.¹⁰⁻¹² In 1957, Morrison¹³ reported fitting 1000 young myopic patients with flat-fitting polymethyl methacrylate contact lenses; none showed any progression of myopia over 2 years of follow-up.

Before 1960, publications had noted only the reduction in myopia from contact lenses fit flatter than the corneal curvature. The first advocacy of orthokeratology occurred at the Second World Contact Lens Congress in Chicago in 1962.¹⁴ At that meeting, the proclaimed father of orthokeratology, George Jessen, lectured on Orthofocus, or The Use of Contact Lenses to Reduce Myopia.¹⁵ In 1967, Nolan reported a successful therapeutic plan to reduce myopia using rigid contact lenses.¹⁶

Widespread use of flat-fitting contact lenses to reduce myopia began, and complications related to this practice soon followed. In 1968, Hartstein argued that keratoconus, or warping, could be caused by hard contact lenses.¹⁷ In 1970, Hartstein and Becker examined a small series of long-term contact lens wearers and suggested that low scleral rigidity was associated with corneal warping; keratoconus or astigmatism was more likely to develop in patients with low rigidity than in those with high scleral rigidity.¹⁸ In 1976, Ing reported irregular astigmatism or corneal warping in 131 patients wearing hard contact lenses.¹⁹

Reports of corneal irregularities made controversial the use of flat-fitting contact lenses to reduce myopia. Four studies evaluating the safety and effectiveness of orthokeratology with polymethyl methacrylate contact lenses were published between 1977 and 1984. At the University of Houston College of Optometry, Kerns²⁰⁻²⁷ conducted a controlled clinical trial over 1000 days comparing 36 eyes subjected to orthokeratology with 26 eyes treated with conventionally fitted rigid contact lenses. Overnight orthokeratology patients experienced marked flattening of the cornea as expected, but the corneal flattening stopped changing after 300 days. Patients showed progressive corneal steepening of the vertical meridian to levels steeper than baseline values, producing long-lasting with-the-rule corneal astigmatism. Changes in refractive error from a 2.6-D decrease to a 1.0-D increase were noted for the OOK group, with induction of average cylinder of 0.42 D. Kerns also noted variability in the fitting process and patient response. Binder et al²⁸ compared 23 OOK patients and 16 rigid contact lens patients and found unpredictable and uncontrolled responses to OOK. Binder concluded that the risk of resulting corneal warpage was small but that it did exist on a short-term basis. The Berkeley Orthokeratology Study assessed safety by monitoring corneal thickness, keratometry, refraction, corneal edema, corneal astigmatism, and endothelial cell density. Reduction in myopia in the OOK group was 1.01 ± 0.87 D, compared with 0.54 ± 0.58 D in the control group. There were minimal changes between control patients and OOK patients in all parameters and no statistical difference in any category, except that the OOK group required 1.25 times as many office visits.^{29,30} The Pacific University study reported effective reduction in myopia of 1.3 D, but results varied from patient to patient.^{31,32}

In 1982, Levy reported the first case of permanent loss of vision in a patient being treated with OOK. Vision loss was attributed to scarring from microbial keratitis.³³ Over the next 25 years, the effectiveness of orthokeratology became

more accepted, but the paucity of data on long-term safety did not allow quantitation of the risk of possible complications associated with widespread use.

The Introduction of Modern Overnight Orthokeratology. Three improvements in technology between 1982 and 2000 led to the reemergence of orthokeratology in 2000. One improvement was the advent of highly oxygen-permeable materials. The first of these new materials was 3M fluoropolymer plastic (3M, St. Paul, MN), which could be used for contact lenses and which provided a significantly higher oxygen transmission, or Dk, value than previously seen, enabling safer contact lens wear during sleep.³⁴ The second improvement was the availability of computer-assisted videokeratography to analyze the surface of the cornea and color-coded maps to provide more information to clinicians on the geographic apical center of the cornea, the optical center of the cornea, and the elevation and curvature of the cornea.^{35–38} Practitioners then could monitor the effects of contact lens wear on corneal topography more accurately.^{39–41} The third improvement was the advent of reverse geometry contact lenses, typified by a flat-back central optical zone and steeper intermediate zone, which permitted more rapid flattening of the central corneal zone than conventional contact lens designs had permitted in the past.^{42–45}

Orthokeratology with reverse-geometry–designed contact lenses reduces myopia by flattening the central cornea. The amount of central cornea flattening measured topographically correlates closely with the amount of myopic reduction. After overnight wear of reverse-geometry contact lenses, histologic and in vivo studies have shown that the corneal epithelium is thinned centrally, which reduces the corneal sagittal height and is responsible for the reduction in myopia.⁴⁶ Overnight wear of reverse-geometry contact lenses has been shown to inhibit central corneal swelling because of central pressure of the flat lens on the central cornea; the peripheral space outside the central flat zone permits stromal edema, accentuating the central corneal flattening with peripheral elevation.⁴⁷ With reverse geometry contact lenses, the secondary curve junction of the posterior lens surface is steep and the periphery of the lens forms a tear reservoir over the midperipheral cornea, effectively redistributing the central edema to the peripheral epithelium.⁴⁸ Thinning of the central epithelium has been demonstrated by optical coherence tomography.⁴⁹

The effectiveness of OOK generally is accepted as a temporary treatment for the reduction of mild myopia.^{1,50,51} Two manufacturers of OOK contact lenses, Paragon Vision Sciences (Mesa, AZ) and Euclid Systems Corporation (Herndon, VA), reported reductions in myopia of up to 1.50 D with no induction of astigmatism in their premarket approval applications to the U.S. Food and Drug Administration (FDA).^{52,53}

Food and Drug Administration Status

In June 2002, Paragon Vision Sciences received FDA approval for the Paragon Corneal Refractive Therapy (CRT), CRT 100, Quadra RG, and Quadra RG 100 (paflucocon B, paflucocon D) RGP contact lenses for the reduction of myopia.⁵² The Paragon CRT was indicated for overnight

wear to correct myopia of up to -6.00 D in eyes with astigmatism of up to 1.75 D, and the Quadra RG was indicated for overnight wear to correct myopia up to -3.00 D in eyes with astigmatism of up to 1.50 D. Approval was granted based on a premarket study of 281 subjects followed up for 9 months. Adverse events reported in the premarket application are listed in Table 1; 4 patients with adverse events left the study. Final approval was given by the FDA without any age restriction, although the FDA advisory panel suggested that approval be limited to individuals 18 years old and older.

In June 2004, Euclid Systems received FDA approval for OOK, and the lens material was subsequently acquired by Bausch & Lomb (Rochester, NY), which now markets the Boston Equalens (BE) material in different designs manufactured by different laboratories.⁵³ The Euclid lens was indicated for overnight wear for temporary reduction of myopia of up to -5.00 D in eyes with astigmatism of up to 1.50 D. One design is the Boston Orthokeratology Oprifoccon A shaping contact lens for overnight wear. Other designs in the Bausch & Lomb Vision Shaping Treatment Method include the Contex OK series (Sherman Oaks, CA), the BE Retainer lens (BE Enterprises, Vancouver, Canada), the Dream Lens (DreimLens, Inc., Indian Harbor Beach, FL), and the Emerald Lens (Euclid Systems). Adverse events reported in the premarket application are listed in Table 1; none were serious.

The FDA requires that all practitioners in the United States be certified to a minimum standard of orthokeratology education. The contact lens manufacturers provide online education and a certification course for practitioners using these lenses. For example, Bausch & Lomb provides an Internet-based training program.⁵⁴ The BE Retainer lens Web site states: “There is a requirement imposed by the HPFB (Health Product Food Branch of Health Canada) and the FDA (Food and Drug Administration in the United States) that all practitioners are certified to a minimum standard of orthokeratology education. To meet this requirement, BE Enterprises and Bausch & Lomb have made an online certification course and test available. It takes around 15 minutes to review and complete the certification course.”⁵⁵ A popular contact lens journal noted: “Becoming certified in corneal reshaping is straightforward. Learning the dynamics of reverse-geometry lenses will set you apart from the average contact lens practitioner. Certification courses cost nothing but a few hours of well-spent time.”⁵⁶

Resource Requirements

The cost of OOK varies. For simple cases, the cost can range from \$1500 to \$2500, depending on the length of treatment and the number of contact lenses prescribed.

Questions for Assessment

The focus of this assessment is to address the following question: Is OOK safe for the temporary treatment of myopia?

Table 1. Data Reported to the Food and Drug Administration in Premarket Approval Application for Orthokeratology Lenses (Level II Evidence)

| Company | No. | Reported Adverse Event/Complication | Comments |
|--|----------------|--|--|
| Boston Orthokeratology Oprofocon A shaping lenses for overnight wear for Bausch & Lomb Vision Shaping Treatment (P10062;S001-S004)* | 191 (378 eyes) | 1 eye: BSCVA reduced to 20/50 (decentered lens) 1 eye: BSCVA reduced to 20/60 (central staining) 1 eye: BSCVA reduced to 20/60 (no reason given) 12 adverse events reported by 10 subjects: 2 eyes: bilateral grade 4 staining with vision decrease to 20/80 1 eye: grade 3 corneal staining (dislodged lens) 1 eye: corneal distortion with vision decrease to 20/200 and rippling on the cornea 2 eyes: bilateral iritis with trace cells and flare in both eyes 1 eye: corneal infiltrates 2 eyes: abrasion (grade 3 staining) | Study period was 9 mos; 29% (110 eyes) discontinued lens wear during the study period. All eyes with acuity reduction reported as returning to normal vision except 2 eyes of 1 subject with ≥ 2 lines loss of BSCVA. Return to pretreatment VA for this subject was not reported on the study form but was reported verbally. 4 patients reporting adverse effects discontinued the study. No age restriction, but boxed warning states that the safety and efficacy has not been studied clinically in adolescent and pediatric subjects (study population was 18 years or older). |
| Paragon CRT, CRT 100, Quadra RG, Quadra RG 100 (paflucocon B, paflucocon D) rigid gas permeable contact lenses for corneal refractive therapy (P870024/S43) [†] | 205 (408 eyes) | 28 eyes (12%): 1 line loss of BSCVA 2 eyes (1%): 2 lines loss of BSCVA 5 eyes (2%): >2 lines loss of BSCVA 1 eye: scratched with lens plunger and/or lens 1 eye: diffuse subepithelial infiltrative keratitis 1 eye: tearing/discomfort | Study enrolled 205 subjects (408 eyes); 121 completed 9 months of treatment; safety analysis was conducted on all eyes. 24 subjects were between the age of 12 and 18 years. The FDA advisory panel recommended that the approved labeling indication should be ≥ 18 years; the FDA did not concur with this recommendation. 83 subjects (40%) discontinued lens wear during the study period: 44 for unacceptable vision; 3 for reasons of comfort; remainder for lack of interest, lost to follow-up, missed visits, other. |

BSCVA = best spectacle-corrected visual acuity; FDA = Food and Drug Administration; VA = visual acuity.

*U.S. Food and Drug Administration Center for Devices and Radiological Health. Euclid Systems Corporation. Summary of safety and effectiveness data from premarket approval application number P010062. 2004. Available at: <http://www.fda.gov/cdrh/pdf/p010062b.pdf>. Accessed May 22, 2008.

[†]U.S. Food and Drug Administration Center for Devices and Radiological Health. Paragon Vision Sciences. Summary of safety and effectiveness data from premarket approval application supplement number P870024/S43. 2002. Available at: <http://www.fda.gov/cdrh/pdf/P870024S043b.pdf>. Accessed May 22, 2008.

Description of Evidence

The peer-reviewed, English language literature was reviewed on December 22, 2005, September 15, 2006, and October 15, 2007, in PubMed (limited to English language) and on January 5, 2006, September 15, 2006, and October 15, 2007, in the Cochrane Library (no language limitations). Key words in the search were the MeSH headings *contact lenses* and *myopia/therapy* or *myopia/rehabilitation* combined with the text word *orthokeratology*. There were no date restrictions on the initial literature search. The authors assessed the 495 citations resulting from the electronic searches and selected 79 citations that definitely or potentially met the inclusion criteria. Any publication on adverse effects or complications in individuals who underwent treatment with overnight use of rigid contact lenses to produce a change in refraction during the day was included; regardless of publication type; patient age; or country of origin. The

reviewers were not masked to either trial results or publication details. Abstracts of meeting presentations are not subject to peer review and are not included in the analysis. Additional studies were identified after the literature searches by surveillance of the literature.

The authors reviewed the full text of the 79 articles and selected 75 that met the inclusion criteria. Under the guidance of the panel methodologist, one of the following ratings of level of evidence was assigned to each of the selected articles. The rating scale is based on the one developed by the British Centre for Evidence-Based Medicine. A level I rating was assigned to well-designed and well-conducted randomized clinical trials; a level II rating was assigned to well-designed case-control and cohort studies and poor-quality randomized studies; and a level III rating was assigned to case series, case reports, and poor-quality cohort and case-control studies. No studies were rated as level I evidence. Information from the premarket applications to the FDA was rated as level II evidence.

There were 2 studies rated as level II evidence.^{57,58} Of the other articles reviewed, 38 were case reports or series (level III evidence) reporting adverse effects from OOK.^{33,59–95} Fourteen articles^{20–30,96–98} reported on orthokeratology in the late 1970s to early 1980s. Thirteen articles were reviews, editorials, commentary, or letters to the editor^{1,2,99–111} and there was one other study¹¹² of microbial flora in tears with OOK. Three articles^{46,47,113} studied the mechanism of action of orthokeratology and 2 articles were experimental.^{114,115} Two articles^{116,117} were not specifically about OOK, but they reported corneal changes in long-term contact lens wearers.

Assessing the safety of treatment usually is more difficult than assessing the benefits, because adverse events can be multiple and generally are not identifiable in advance. Adverse events often are not reported or are reported inconsistently, and reports are difficult to retrieve from the published literature because of poor indexing.¹¹⁸ Case reports and case series represent observations for an undefined population of OOK users and are not collected in a standardized manner. Without knowledge of the number of users, an accurate rate of adverse events is impossible to calculate. Only long-term prospective studies and randomized controlled trials, wherein the number of patients experiencing an adverse event and the total number of patients undergoing OOK are known, can provide a more reliable measure of risk. Unfortunately, none of the peer reviewed literature on OOK could be rated as level I evidence, thus limiting the quality of any safety and risk assessment for OOK.

Published Results

Table 1 lists adverse events from the premarket approval applications to the FDA. In randomized controlled studies of OOK rated as level II evidence, Lipson et al⁵⁷ reported no adverse events in 15 months of follow-up of 65 adult patients, and Lui and Edwards⁵⁸ reported no adverse events in 100 days of follow-up of 14 patients. In level III-rated evidence, Mika et al⁶⁰ reported no adverse events in 6 months of follow-up of 16 girls (age range, 10–16 years), and Soni and Nguyen⁶¹ reported 9 adverse events in 1 year of follow-up (n = 201). One patient had recurrent corneal erosions and the other 8 events were not sight threatening and resolved completely.⁶¹ In an article identified by surveillance of the literature, Lipson reported results of a retrospective review of 296 patients undergoing OOK over a 4-year period.¹¹⁹ There were 3 adverse events (defined as microbial keratitis or a corneal ulcer, a corneal abrasion requiring medical treatment, or a corneal scar) during the study period that did not result in a loss of best-corrected visual acuity. There was no difference in safety and efficacy of OOK in children younger than 12 years compared with children and adults older than 12 years of age.¹¹⁹

Table 2 lists reports of infectious keratitis. Some corneal ulcers were reported in more than 1 publication, and care was taken to eliminate duplications in review articles and to list each adverse event only once. As previously noted, the value of the data is limited, because no denominator exists

for the treatment population and the total number of patients undergoing OOK is unknown. Table 3 lists reports of other adverse events associated with OOK; these additional complications are discussed below.

Infectious Keratitis

Reports of microbial keratitis associated with the use of OOK lenses from 5 different centers on 3 different continents were published simultaneously in the journal *Cornea* in 2005.^{59,72,87,90,91} The accompanying commentary raised 3 significant concerns about the undue occurrence of infectious microbial keratitis in these reports.¹⁰⁶ Most of these infections were central and severe, caused by aggressive organisms such as gram-negative rods or *Acanthamoeba* that are capable of causing significant vision loss from corneal scarring. Second, most cases occurred in children or adolescents. Third, the infections were associated with multiple brands of RGP contact lenses and occurred in different countries. These simultaneous reports of cases of microbial keratitis instigated safety concerns about OOK and scrutiny of the procedure.

Ladage et al¹¹⁵ reported a statistically significant increase in binding of *Pseudomonas aeruginosa* to the rabbit cornea in the presence of contact lens wear. They noted greater cornea *Pseudomonas* binding to hyper-oxygen transmitting polymer RGP contact lenses when fitted as OOK lenses compared with the alignment fit RGP lenses supporting exposed risk for OOK versus alignment-fit RGP contact lenses, even with the highest Dk value (most oxygen permeable) materials. Under alignment fit conditions, clinical RGP contact lens wear of the highest Dk material showed no increase in *P. aeruginosa* binding after 30 nights of human wear.¹²⁰ This evidence suggests that the OOK fit produces the higher risk for microbial keratitis compared with just the overnight wear. Ladage et al also noted an increase in central corneal epithelial thinning, stromal thickening, and surface cell damage with overnight contact lenses.

Asbell¹¹⁴ reported that *P. aeruginosa* binding was more common in smooth epithelial cells found in deeper cell layers and less in mature cells with microvilli. In individual cells with both smooth and villous surfaces, *Pseudomonas* preferentially bound to the smooth areas of the cells.

Boost and Cho¹¹² studied flora in 41 students with multiple conjunctival cultures before and during OOK, finding no significant difference in levels or type of pathogens over time with contact lens wear. They concluded that ocular flora was not altered by OOK, but variations in contact lens care and cleaning and disinfection regimens were more likely to influence bacteria present. Microbial keratitis, then, likely results from the introduction of opportunistic pathogens already present on the ocular surface into compromised corneal epithelial cells.

More than 100 cases of infectious keratitis associated with OOK have been reported since 2001 in the literature reviewed for this assessment; the listing in Table 2 shows the case reports and offending organisms. Of these, *Pseudomonas* was the leading pathogen, with 39 documented cases. In addition, there were 32 patients with *Acanthamoeba*, 4 with *Serratia* species, 3 with fungal ulcers, 2 with *Staphylococcus* species, and 1 with *Nocardia*. Approx-

Table 2. Infectious Keratitis Associated with

| Author, Year | Country | Level of Evidence | No. (Patients) | Age (yrs) |
|--|-----------|-------------------|---------------------|----------------------------|
| Araki-Sasaki et al, 2005 ⁵⁹ | Japan | III | 1 | 17 |
| Chen et al, 2001 ⁶⁴ | Taiwan | III | 1 | 9 |
| Hsiao et al, 2004 ⁷³ | Taiwan* | III | 6 | Average, 13 (range, 9–17) |
| Hsiao et al, 2005 ⁷² | Taiwan* | III | 20 patients/21 eyes | Average, 14 (range, 9–21) |
| Hsiao et al, 2007 ⁷⁴ | Taiwan* | III | 8 | Mean, 11.2 |
| Hutchinson & Apel, 2002 ⁷⁵ | Australia | III | 2 | 60 29 |
| Lang & Rah, 2004 ⁷⁷ | USA | III | 2 | 29 12 |
| Lau et al, 2003 ⁷⁸ | Taiwan | III | 2 | 11 11 |
| Lu et al, 2001 ⁸⁰ | China | III | 16 | — |
| Macasai, 2005 ⁸¹ | USA | III | 2 | 9 11 |
| Poole et al, 2003 ⁸² | UK | III | 1 | 22 |
| Priel et al, 2006 ⁸³ | Israel | III | 1 | 16 |
| Robertson et al, 2007 ¹²² | USA | III | 1 | 19 |
| Sun et al, 2006 ⁸⁶ | China | III | 28 | Average, 16 (range, 10–21) |
| Tseng et al, 2005 ⁸⁷ | Taiwan | III | 9/10 eyes | Mean, 12.3 (range, 8–17) |
| Wang & Lim, 2003 ⁸⁸ | Singapore | III | 1 | 14 |
| Watt et al, 2007 ⁸⁹ | Australia | III | 7 | Average, 17 (range, 12–22) |
| Wilhelmus 2005 ⁹⁰ | USA | III | 1 | 16 |
| Xuguang et al, 2003 ⁹⁵ | China | III | 4 | Average, 17 (range, 15–19) |
| Yepes et al, 2005 ⁹¹ | Canada | III | 3 | 41 14 12 |
| Ying-Cheng et al, 2006 ⁹² | Taiwan | III | 1 | 16 |
| Young et al, 2003 ⁹⁴ | Hong Kong | III | 1 | 37 |
| Young et al, 2004 ⁹³ | Hong Kong | III | 6 | Mean, 12.1 (range, 9–14) |

BCVA = best-corrected visual acuity; BSCVA = best spectacle-corrected visual acuity; UK = United Kingdom; USA = United States of America; VA = visual acuity.

*These studies report cases at the Chang Gung Memorial Hospital, Taipei, and may be duplicated reports.

Orthokeratology in Published Reports

| Type of Study | Reported Pathogen | Comments/Visual Acuity after Treatment |
|--|---|--|
| Case report | <i>Pseudomonas</i> | Glycocalyx biofilm formation confirmed on contact lenses No loss of BCVA |
| Single case report | <i>Serratia marcescens</i> | 9 yr-old had 6 mos orthokeratology in USA; BCVA after treatment, 20/20 |
| Noncomparative case series | <i>Pseudomonas</i> | BCVA range 20/20 to 20/200; 4 lost BCVA |
| Retrospective noncomparative case series | 9, <i>Pseudomonas</i> 2, <i>Staphylococcus</i> 1, <i>Serratia</i> 1, <i>Acanthamoeba</i> 8, negative culture results | Cases occurred from January 2001 through December 2002 Final VA range 20/20 to 20/100; 4 lost BCVA Cases occurred from April 2000 to March 2003; there is an overlap with cases reported in Hsiao 2004 |
| Case series | 4, gram-negative bacteria 4, negative culture results | Cases occurred from July 1, 1998, through December 31, 2002; there is an overlap with cases reported in Hsiao 2004 and Hsiao 2005 |
| Case report | 1, <i>Pseudomonas</i> 1, <i>Acanthamoeba</i> | BCVA, 20/40 (unchanged) BCVA, 20/120 |
| Noncomparative case series | 1, unknown 1, <i>Serratia</i> | No loss of BCVA |
| Case report | <i>Pseudomonas</i> | BCVA left eye, 20/200 BCVA, 20/25 |
| Noncomparative case series | 7, <i>Pseudomonas</i> 8, <i>Acanthamoeba</i> 1, Mycotic keratitis | 9 required lamellar keratoplasty or penetrating keratoplasty |
| Case report | 1, <i>Pseudomonas</i> 1, <i>Haemophilus influenzae</i> | BCVA, 20/30 Each patient lost 2 lines of BCVA |
| Single case report | Unknown | BCVA 20/30 |
| Single case report | <i>Pseudomonas</i> | BSCVA 20/50 |
| Single case report | <i>Acanthamoeba</i> | BCVA, light perception with projection. Additional complications: secondary angle-closure glaucoma, mature cataract |
| Noncomparative case series | 13, <i>Acanthamoeba</i> 8, <i>Pseudomonas</i> 2, Fungus 1, <i>Nocardia</i> 1, <i>Providencia stuartii</i> 1, gram-negative rods 2, negative | Cases occurred from March 2000 through August 2001; 3 of the cases reported here are in the time range for the cases reported in Xuguang 2003 (same first author) VA after treatment was not available for the fourth case. |
| Noncomparative case series | Microbial keratitis; 90% with central corneal infiltrates 3, <i>Acanthamoeba</i> 1, <i>Pseudomonas</i> 1, gram negative 4, negative results | Denominator unknown; type of lens and details of wear unknown 4 eyes BCVA 20/30 or worse; 1 eye with hand movements only |
| Single case report | <i>P. aeruginosa</i> keratitis; stellate-shaped central corneal infiltrate | BCVA 20/25 |
| Survey | 3, <i>Pseudomonas</i> 1, <i>Acanthamoeba</i> 3, Unknown | 2 cases were previously reported by Hutchinson and are not included here No loss of BCVA |
| Single case report | <i>Acanthamoeba</i> | VA 20/100 |
| Case report | <i>Acanthamoeba</i> | Cases occurred in June 2001 (n = 1), August 2001 (n = 2), and February 2002 (n = 1) 1 case no VA impairment; VA in other cases from 20/50 to 20/75 |
| Case report | 1, <i>Acanthamoeba</i> 1, <i>Serratia</i> | BCVA, hand movements BCVA, 20/80 |
| Single case report | 1, <i>Pseudomonas</i> <i>P. aeruginosa</i> <i>P. putida</i> <i>Burkholderia cepacia</i> | BCVA, 20/20 BCSVA, 20/20 |
| Single case report | <i>Pseudomonas</i> | BCVA, 20/30 |
| Noncomparative case series | 5, <i>Pseudomonas</i> 1, unknown | All lost BCVA; BSCVA range, 20/20–20/200 |

Table 3. Other Complications of Orthokeratology

| Author/Year | Country | Level of Evidence | Number | Type of Study | Adverse Effect/Complication | Comments |
|--------------------------------------|-----------|-------------------|-------------------------|--|-----------------------------|---|
| Hiraoka et al, 2004 ⁶⁹ | Japan | III | 31 patients/ 52 eyes | Prospective noncomparative case series | None | No endothelial cell loss noted with specular microscopy |
| Berntsen et al, 2005 ⁶³ | USA | III | 20 | Prospective noncomparative case series | Astigmatism | Higher-order aberrations increased in 5-mm pupils from baseline after 1 month wear ($P < 0.0001$) |
| Hiraoka et al, 2005 ⁷¹ | Japan | III | 39 patients/ 64 eyes | Prospective noncomparative case series | Astigmatism | Higher-order aberrations in 64 eyes of 39 patients |
| Joslin et al, 2003 ⁷⁶ | USA | III | 9 patients/ 18 eyes | Prospective noncomparative case series | Astigmatism | Higher-order aberrations in 18 eyes of 9 patients |
| Stillitano et al, 2004 ⁸⁵ | Brazil | III | 14 patients/ 26 eyes | Prospective cohort study | Astigmatism | Higher-order aberrations, especially spherical aberration and coma, increased from baseline after night 1 ($P = 0.006$) and night 8 of wear ($P = 0.004$) |
| Cheung et al, 2006 ⁶⁵ | Hong Kong | III | 1 | Single case report | Concentric white lines | Concentric white lines in paracentral cornea representing nerve bundles of the sub-basal plexus |
| Cho et al, 2005 ⁶⁶ | Hong Kong | III | 35 | Noncomparative case series | Corneal pigmentation | Pigment present in 90% of 35 patients followed for 1 year |
| Rah et al, 2002 ⁸⁴ | USA | III | 6 | Noncomparative case series | Corneal pigmentation | 5 of 6 patients followed 6 months to 2 years |
| Liang et al, 2003 ⁷⁹ | Taiwan | III | 2 | Case report | Corneal pigmentation | 2 patients |
| Cho et al, 2002 ⁶⁷ | Hong Kong | III | 1 | Single case report | Corneal pigmentation | 1 patient |
| Hiraoka et al, 2004 ⁷⁰ | Japan | III | 1 | Single case report | Corneal pigmentation | 1 patient |
| Levy et al, 1982 ³³ | Canada | III | 1 | Single case report | Recurrent corneal erosion | 1983 series, symptoms persisted 1 year |
| Gupta & Weinreb, 1997 ⁶⁸ | USA | III | 1 | Single case report | Infected filtering bleb | 4-year status post-trabeculectomy with mitomycin-C |

imately one third of the infectious keratitis cases were those reported in *Cornea* articles in 2005.

Interpreting these data to evaluate the safety of OOK is difficult, because the denominator of all orthokeratology patients is unknown. After the first reported cases in China, Taiwan, Hong Kong, and Japan, government regulation of orthokeratology was instituted for the expressed purpose of reducing complications of OOK.^{1,110,111} In China, reported complications led to the registration of approved contact lenses and government authorization of orthokeratology providers.¹¹⁰

Endothelium

Overnight orthokeratology use for 1 year does not influence density or the morphologic features of corneal endothelial cells when assessed by specular microscopy, although the range of insult that could be detected by specular microscopy is not known.⁶⁹ The coefficient of variation of endothelial cell density was 22.3, a large number but consistent with conventional specular microscopy data. Corneal thickness is not a useful measure of corneal health because the intentional flattening of the central epithelium makes pachymetry measurements artifactually low. There was no change in polymegathism or polymorphism noted in study patients compared with normal subjects. The Berkeley

Study reported that the endothelium was not adversely affected by orthokeratology during the 1-year follow-up.²⁹ Only longer-term studies can establish the risks of endothelial dysfunction.

Induced Astigmatism

Higher-order positive spherical aberration is induced by OOK.^{63,76,85} Hiraoka et al⁷¹ reported that 64 eyes of 39 patients undergoing OOK had successfully reduced myopia from -2.6 D to -0.17 D, but increased third- and fourth-order aberration significantly in the vertical and horizontal corneal axis. The increase of higher-order aberration is similar to that observed after radial keratotomy and LASIK (i.e., surgically induced).

Concentric White Lines

Fine concentric white lines in the paracentral epithelium were described by Cheung et al.⁶⁵ These fibrillary lines were similar to those seen in patients with keratoconus and were thought to represent nerve bundles in the subbasilar plexus. In 1975, Bron¹²¹ reported single lines in normal patients that ultimately were determined to be corneal nerves. These concentric lines are of no known clinical significance other than that they were induced by OOK.

Corneal Epithelial Iron Lines

Multiple observers have reported pigmented iron lines in the paracentral cornea in a number of patients. Cho et al⁶⁶ reported corneal pigmented iron lines in 35 patients undergoing OOK who were followed up for 12 months. The lines were noted in 17% of patients at 3 months, 49% of patients at 6 months, and 90% of patients at 12 months in both eyes. Rah et al⁸⁴ noted an iron line in 5 of 6 patients fitted with OOK lenses; 5 patients were fitted with CRT lenses (Paragon), and 4 of 5 iron lines were in patients with the CRT lens. One patient fitted with the Dream lens design also had an iron line. Additional iron lines similar to Hudson-Stähli lines were reported in OOK patients by Liang et al,⁷⁹ Cho et al,⁶⁷ and Hiraoka et al.⁷⁰ The clinical significance of the iron line is probably minimal.

Recurrent Corneal Erosion

Recurrent corneal erosion syndrome after OOK was reported by Levy in 1980.³³ Symptoms persisted for 2 weeks and the patient experienced further recurrences during the next 12 months. Before beginning orthokeratology treatment, the patient had been examined by an ophthalmologist who found that the examination showed normal results except for a slightly low Schirmer test score. Soni and Nguyen⁶¹ reported on 1 patient who had recurrent corneal erosions in the left eye only. The small punctate abrasions cleared in several days and the OOK treatment was stopped.

Infected Filtering Bleb

In 1997, Gupta and Weinreb⁶⁸ reported an infected filtering bleb in a patient who began an orthokeratology program 10 weeks earlier. The patient was fitted with a flatter pair of contact lenses 1 week before seeking treatment for an avascular bleb with a yellowish infiltrate. The patient responded to treatment with fortified topical antibiotics and systemic antibiotics, and 1 month later seemed to be normal.

Discussion

The safety of orthokeratology is difficult to assess. In the 2 premarket applications, 1 did not study patients younger than 18 years, and in the other, the FDA advisory panel recommended approval for individuals 18 years of age and older.

Early case reports of complications, especially in children, may reflect local rather than national practices. Details of individual complications such as the specific contact lens, wear regimen, and compliance with the cleaning regimen frequently are not reported. As with most clinical diseases, underreporting of complications is assumed. After initial reports, journal editors may not consider additional reports as having much value after the first cases are in print.

Many cases of infectious keratitis occurred in teenagers and children. The large number of children and adolescents in these series and the risk of sight-threatening complications necessitate the highest level of vigilance. The wide

variation in organisms, treatment, and patients led to wide variation in outcomes, with some patients losing vision and other patients retaining good vision. Therein lies one difficulty of evaluating the safety of OOK: not all patients who had infectious keratitis sustained damage because of the complication. However, damage assessment is only one aspect of evaluation of risk, and the OOK process puts a number of patients at risk for potentially vision-threatening complications that they may not encounter otherwise. The severity of the adverse event often is determined by the speed of diagnosis and the effectiveness of therapy administered by the treating physician.

The *Acanthamoeba* keratitis cases were severe and sight-threatening and can be bilateral.¹²² The *Acanthamoeba* keratitis cases in children may be the result of deficient levels of tear film immunoglobulin A,¹²³ which have been shown to be reduced in patients with clinical *Acanthamoeba* keratitis. This evidence suggests that exposing children as young as 8 years to the possibility of bilateral *Acanthamoeba* keratitis infection from OOK requires a solid rationale for use in that group of patients.

Rinsing RGP contact lenses with tap water is a common practice and is mentioned on the package insert of RGP contact lenses. The use of nonsterile water (e.g., tap water) by children and adults on RGP contact lenses and contact lens cases should be discouraged in favor of commercially available multipurpose contact lens solutions, and practitioners should recommend strongly the complete elimination of tap water from all steps in OOK regimens.¹²⁴

Fitting reverse-geometry contact lenses according to K-readings and fluorescein patterns is subject to wide clinical variation from practitioner to practitioner. The interpretation of fluorescein patterns requires skill and experience; the central flat zone of a reverse-geometry contact lens is more discernible to experienced practitioners. As with any technique, a learning curve for practitioners influences the effectiveness and the safety of OOK for individual patients.

Because specific risks associated with OOK have not been elucidated or quantified, it becomes imperative that patients, families, and practitioners realize that the risk factors associated with orthokeratology are poorly understood and extend throughout the use of the contact lenses. In the studies reviewed, many patients wore hard contact lenses for more than 2 years before encountering vision loss resulting from microbial keratitis.

The prevalence and incidence of complications associated with OOK have not been determined. Complications have been described only in case series and case reports representing observations in undefined populations of OOK users. Furthermore, both data collection and reporting lack standardization. The large number of children and adolescents in these series and the risk of sight-threatening complications in children and adolescents necessitates the highest level of vigilance.

Risk factors for various complications of OOK cannot be determined because there is variation in patient characteristics, provider credentialing and training, contact lens type, contact lens fitting practice, wear regimen, care regimen, compliance, and follow-up among the various case reports and series and in clinical practice. Clinician training, skill,

and experience also may be factors in the safety of OOK. For these reasons, a wide margin of safety should be built into OOK practice, and regulation by governmental or other appropriate bodies may play a role in ensuring that appropriate standards of care are followed.

There are insufficient data to compare the risks of OOK with those associated with other types of contact lenses or refractive surgery. The increased risk of infectious keratitis with overnight contact lens wear compared with daytime contact lens wear is addressed in the Refractive Errors & Refractive Surgery Preferred Practice Pattern.¹²⁵ The risk standard that myopia correction is judged against is eyeglass wear, which carries little risk. Comparing OOK with surgical correction, such as LASIK, is not appropriate because LASIK is an invasive procedure. LASIK is intended to alter the shape of the cornea permanently by removing corneal tissue and has its own risks and complications; it is not FDA-approved for use in children. Practitioners who offer other treatments to correct myopia should evaluate the risks of OOK with respect to the other treatments commensurate with their abilities and local standards.¹⁰⁵ Ultimately, safety is more likely to be achieved with ethical and knowledgeable practitioners and educated patients. The application of OOK in children and adolescents should be undertaken very cautiously, and the practice of OOK should be pursued in all patients with these goals in mind.

Future Research

Future research should be directed at assessing the rate of infectious keratitis among OOK users and whether the rate varies by age or clinical characteristics such as contact lens type, wear regimen, or fitting parameters. Sufficiently large, well-designed cohort or randomized controlled studies are needed to provide a more reliable measure of the risks of treatment and to identify risk factors for complications. Overnight orthokeratology for slowing the progression of myopia in children also needs to be assessed by well-designed and properly conducted controlled trials to determine efficacy. Research also should consider contact lens material, contact lens design, and treatment schedule to optimize refractive effect and to minimize the risk of infectious keratitis. Finally, continuing basic science research into the pathogenesis, prevention, and treatment of microbial keratitis is warranted, with the goal of saving vision in patients affected by this complication.

References

1. Swarbrick HA. Orthokeratology review and update. *Clin Exp Optom* 2006;89:124–43.
2. Kwok LS, Pierscionek BK, Bullimore M, et al. Orthokeratology for myopic children: wolf in sheep's clothing? *Clin Experiment Ophthalmol* 2005;33:343–7.
3. Quek TP, Chua CG, Chong CS, et al. Prevalence of refractive errors in teenage high school students in Singapore. *Ophthalmic Physiol Opt* 2004;24:47–55.
4. Woo WW, Lim KA, Yang H, et al. Refractive errors in medical students in Singapore. *Singapore Med J* 2004;45:470–4.
5. Katz J, Schein OD, Levy B, et al. A randomized trial of rigid gas permeable contact lenses to reduce progression of children's myopia. *Am J Ophthalmol* 2003;136:82–90.
6. Walline JJ, Jones LA, Mutti DO, Zadnik K. A randomized trial of the effects of rigid contact lenses on myopia progression. *Arch Ophthalmol* 2004;122:1760–6.
7. Cho P, Cheung SW, Edwards M. The Longitudinal Orthokeratology Research in Children (LORIC) in Hong Kong: a pilot study on refractive changes and myopic control. *Curr Eye Res* 2005;30:71–80.
8. Waring GO III. Orthokeratology. *Surv Ophthalmol* 1980;24:291.
9. Pearson RM. Kalt, keratoconus, and the contact lens. *Optom Vis Sci* 1989;66:643–6.
10. Hirsch MJ. The prevention and/or cure of myopia. *Am J Optom Arch Am Acad Optom* 1965;42:327–36.
11. Hodd FA. Changes in corneal shape induced by the use of alignment fitted corneal lenses. *Contacto* 1965;9:18–24.
12. Morrison RJ. Observations on contact lenses and the progression of myopia. *Contacto* 1958;2:20–5.
13. Morrison RJ. Contact lenses and the progression of myopia. *J Am Optom Assoc* 1957;28:711, 713.
14. Neilson RH, Grant SC, May CH. Emmetropization through contact lenses. *Contacto* 1964;8:20–1.
15. Jessen GN. Orthofocus techniques. *Contacto* 1962;6:200–4.
16. Nolan J. Myopia control with contact lenses. *Contacto* 1967;11:24–7.
17. Hartstein J. Keratoconus that developed in patients wearing corneal contact lenses: report of four cases. *Arch Ophthalmol* 1968;80:345–6.
18. Hartstein J, Becker B. Research into the pathogenesis of keratoconus. A new syndrome: low ocular rigidity, contact lenses, and keratoconus. *Arch Ophthalmol* 1970;84:728–9.
19. Ing MR. The development of corneal astigmatism in contact lens wearers. *Ann Ophthalmol* 1976;8:309–14.
20. Kerns RL. Research in orthokeratology. Part III: results and observations. *J Am Optom Assoc* 1976;47:1505–15.
21. Kerns RL. Research in orthokeratology. Part II: experimental design, protocol and method. *J Am Optom Assoc* 1976;47:1275–85.
22. Kerns RL. Research in orthokeratology. Part I: introduction and background. *J Am Optom Assoc* 1976;47:1047–51.
23. Kerns RL. Research in orthokeratology. Part VII: examination of techniques, procedures and control. *J Am Optom Assoc* 1977;48:1541–53.
24. Kerns RL. Research in orthokeratology. Part VI: statistical and clinical analyses. *J Am Optom Assoc* 1977;48:1134–47.
25. Kerns RL. Research in orthokeratology. Part V: results and observations—recovery aspects. *J Am Optom Assoc* 1977;48:345–59.
26. Kerns RL. Research in orthokeratology. Part IV: results and observations. *J Am Optom Assoc* 1977;48:227–38.
27. Kerns RL. Research in orthokeratology. Part VIII: results, conclusions and discussion of techniques. *J Am Optom Assoc* 1978;49:308–14.
28. Binder PS, May CH, Grant SC. An evaluation of orthokeratology. *Ophthalmology* 1980;87:729–44.
29. Polse KA, Brand RJ, Keener RJ, et al. The Berkeley Orthokeratology Study, part III: safety. *Am J Optom Physiol Opt* 1983;60:321–8.
30. Polse KA, Brand RJ, Schwalbe JS, et al. The Berkeley Orthokeratology Study, part II: efficacy and duration. *Am J Optom Physiol Opt* 1983;60:187–98.
31. Coon LJ. Orthokeratology. Part I: historical perspective. *J Am Optom Assoc* 1982;53:187–95.

32. Coon LJ. Orthokeratology. Part II: evaluating the Tabb method. *J Am Optom Assoc* 1984;55:409–18.
33. Levy B. Permanent corneal damage in a patient undergoing orthokeratology. *Am J Optom Physiol Opt* 1982;59:697–9.
34. MacKeen DL, Sachdev M, Ballou V, Cavanagh HD. A prospective multicenter clinical trial to assess safety and efficacy of Menicon SF-P RGP lenses for extended wear. *CLAO J* 1992;18:183–6.
35. Gormley DJ, Gersten M, Koplin RS, Lubkin V. Corneal modeling. *Cornea* 1988;7:30–5.
36. Wasserman D, Itzkowitz J, Kamenar T, Asbell PA. Corneal topographic data: its use in fitting aspheric contact lenses. *CLAO J* 1992;18:83–5.
37. Wilson SE, Klyce SD. Advances in the analysis of corneal topography. *Surv Ophthalmol* 1991;35:269–77.
38. Phillips AJ. Orthokeratology—an alternate to excimer laser? *J Br Contact Lens Assoc* 1995;18:65–71.
39. Gambino MJ. Classic orthokeratology vs. modern orthokeratology. *Contacto* 1996;39:31–2.
40. Day JH. Corneal eccentricity and fitting ortho-k molds. *Contacto* 1995;38:22–7.
41. Lebow KA. Using corneal topography to evaluate the efficacy of orthokeratology fitting. *Contacto* 1996;39:20–6.
42. Winkler TD, Kame RT. Basic techniques of accelerated orthokeratology. In: *Orthokeratology Handbook*. Newton, MA: Butterworth-Heinemann, 1995:21
43. Winkler TD. Accelerated orthokeratology: a case report. *Clin Exp Optom* 1995;78:11–3.
44. Mountford J. An analysis of the changes in corneal shape and refractive error induced by accelerated orthokeratology. *Int Contact Lens Clin* 1997;24:128–43.
45. Mountford J. Retention and regression of orthokeratology with time. *Int Contact Lens Clin* 1998;25:59–64.
46. Alharbi A, Swarbrick HA. The effects of overnight orthokeratology lens wear on corneal thickness. *Invest Ophthalmol Vis Sci* 2003;44:2518–23.
47. Alharbi A, La Hood D, Swarbrick HA. Overnight orthokeratology lens wear can inhibit the central stromal edema response. *Invest Ophthalmol Vis Sci* 2005;46:2334–40.
48. Nichols JJ, Marsich MM, Nguyen M, et al. Overnight orthokeratology. *Optom Vis Sci* 2000;77:252–9.
49. Wang J, Fonn D, Simpson TL, et al. Topographical thickness of the epithelium and total cornea after overnight wear of reverse-geometry rigid contact lenses for myopia reduction. *Invest Ophthalmol Vis Sci* 2003;44:4742–6.
50. Norman CW. Current research in corneal reshaping. *Cont Lens Spectr* [serial online] October 2005. Available at: <http://www.clspectrum.com/article.aspx?article=12890>. Accessed May 22, 2008.
51. Walline JJ, Holden BA, Bullimore MA, et al. The current state of corneal reshaping. *Eye Contact Lens* 2005;31:209–14.
52. U.S. Food and Drug Administration Center for Devices and Radiological Health. Paragon Vision Sciences. Summary of safety and effectiveness data from premarket approval application supplement number P870024/S43. 2002. Available at: <http://www.fda.gov/cdrh/pdf/P870024S043b.pdf>. Accessed May 22, 2008.
53. U.S. Food and Drug Administration Center for Devices and Radiological Health. Euclid Systems Corporation. Summary of safety and effectiveness data from premarket approval application number P010062. 2004. Available at: <http://www.fda.gov/cdrh/pdf/p010062b.pdf>. Accessed May 22, 2008.
54. Bausch & Lomb. Vision Shaping Treatment VST online certification. Available at: http://www.bausch.com/en_US/ecp/visioncare/product/general/vst_cert.aspx. Accessed May 22, 2008.
55. BE Enterprises Inc. Bausch & Lomb Vision Shaping Treatment VST: Getting Started with BE Retainer. Available at: <http://www.beretainer.com/main.aspx?PageID=20103>. Accessed May 22, 2008.
56. Anderson DM. Is your practice ready for a corneal topographer? *Cont Lens Spectr* [serial online] August 2006. Available at: <http://www.clspectrum.com/article.aspx?article=13085>. Accessed May 22, 2008.
57. Lipson MJ, Sugar A, Musch DC. Overnight corneal reshaping versus soft disposable contact lenses: vision-related quality-of-life differences from a randomized clinical trial. *Optom Vis Sci* 2005;82:886–91.
58. Lui WO, Edwards MH. Orthokeratology in low myopia. Part 2: corneal topographic changes and safety over 100 days. *Cont Lens Anterior Eye* 2000;23:90–9.
59. Araki-Sasaki K, Nishi I, Yonemura N, et al. Characteristics of Pseudomonas corneal infection related to orthokeratology. *Cornea* 2005;24:861–3.
60. Mika R, Morgan B, Cron M, et al. Safety and efficacy of overnight orthokeratology in myopic children. *Optometry* 2007;78:225–31.
61. Soni PS, Nguyen TT, XO Overnight Orthokeratology Study Group. Overnight orthokeratology experience with XO material. *Eye Contact Lens* 2006;32:39–45.
62. Mountford J, Pesudovs K. An analysis of the astigmatic changes induced by accelerated orthokeratology. *Clin Exp Optom* 2002;85:284–93.
63. Berntsen DA, Barr JT, Mitchell GL. The effect of overnight contact lens corneal reshaping on higher-order aberrations and best-corrected visual acuity. *Optom Vis Sci* 2005;82:490–7.
64. Chen KH, Kuang TM, Hsu WM. Serratia marcescens corneal ulcer as a complication of orthokeratology. *Am J Ophthalmol* 2001;132:257–8.
65. Cheung SW, Cho P, Bron AJ, et al. Case report: the occurrence of fibrillary lines in overnight orthokeratology. *Ophthalmic Physiol Opt* 2006;26:525–31.
66. Cho P, Cheung SW, Mountford J, Chui WS. Incidence of corneal pigmented arc and factors associated with its appearance in orthokeratology. *Ophthalmic Physiol Opt* 2005;25:478–84.
67. Cho P, Chui WS, Mountford J, Cheung SW. Corneal iron ring associated with orthokeratology lens wear. *Optom Vis Sci* 2002;79:565–8.
68. Gupta N, Weinreb RN. Filtering bleb infection as a complication of orthokeratology [letter]. *Arch Ophthalmol* 1997;115:1076.
69. Hiraoka T, Furuya A, Matsumoto Y, et al. Influence of overnight orthokeratology on corneal endothelium. *Cornea* 2004;23(suppl):S82–6.
70. Hiraoka T, Furuya A, Matsumoto Y, et al. Corneal iron ring formation associated with overnight orthokeratology. *Cornea* 2004;23(suppl):S78–81.
71. Hiraoka T, Matsumoto Y, Okamoto F, et al. Corneal higher-order aberrations induced by overnight orthokeratology. *Am J Ophthalmol* 2005;139:429–36.
72. Hsiao CH, Lin HC, Chen YF, et al. Infectious keratitis related to overnight orthokeratology. *Cornea* 2005;24:783–8.
73. Hsiao CH, Yeh LK, Chao AN, et al. Pseudomonas aeruginosa corneal ulcer related to overnight orthokeratology. *Chang Gung Med J* 2004;27:182–7.
74. Hsiao CH, Yeung L, Ma DH, et al. Pediatric microbial keratitis in Taiwanese children: a review of hospital cases. *Arch Ophthalmol* 2007;125:603–9.
75. Hutchinson K, Apel A. Infectious keratitis in orthokeratology. *Clin Experiment Ophthalmol* 2002;30:49–51.
76. Joslin CE, Wu SM, McMahon TT, Shahidi M. Higher-order

- wavefront aberrations in corneal refractive therapy. *Optom Vis Sci* 2003;80:805–11.
77. Lang J, Rah MJ. Adverse corneal events associated with corneal reshaping: a case series. *Eye Contact Lens* 2004;30:231–3; discussion 242–3.
 78. Lau LI, Wu CC, Lee SM, Hsu WM. Pseudomonas corneal ulcer related to overnight orthokeratology. *Cornea* 2003;22:262–4.
 79. Liang JB, Chou PI, Wu R, Lee YM. Corneal iron ring associated with orthokeratology. *J Cataract Refract Surg* 2003;29:624–6.
 80. Lu L, Zou L, Wang R. Orthokeratology induced infective corneal ulcer [in Chinese]. *Zhonghua Yan Ke Za Zhi* 2001;37:443–6.
 81. Macsai MS. Corneal ulcers in two children wearing Paragon Corneal Refractive Therapy lenses. *Eye Contact Lens* 2005;31:9–11.
 82. Poole TR, Frangouli O, Ionides AC. Microbial keratitis following orthokeratology [letter]. *Eye* 2003;17:440–1.
 83. Priel A, Grinbaum A, Barequet IS. Severe Pseudomonas aeruginosa keratitis shortly after initiation of corneal refractive therapy. *Eye Contact Lens* 2006;32:1–2.
 84. Rah MJ, Barr JT, Bailey MD. Corneal pigmentation in overnight orthokeratology: a case series. *Optometry* 2002;73:425–34.
 85. Stillitano IG, Chalita MR, Schor P, et al. Corneal changes and wavefront analysis after orthokeratology fitting test. *Am J Ophthalmol* 2007;144:378–86.
 86. Sun X, Zhao H, Deng S, et al. Infectious keratitis related to orthokeratology. *Ophthalmic Physiol Opt* 2006;26:133–6.
 87. Tseng CH, Fong CF, Chen WL, et al. Overnight orthokeratology-associated microbial keratitis. *Cornea* 2005;24:778–82.
 88. Wang JC, Lim L. Unusual morphology in orthokeratology contact lens-related cornea ulcer. *Eye Contact Lens* 2003;29:190–2.
 89. Watt KG, Boneham GC, Swarbrick HA. Microbial keratitis in orthokeratology: the Australian experience. *Clin Exp Optom* 2007;90:182–7; quiz 188–9.
 90. Wilhelmus KR. Acanthamoeba keratitis during orthokeratology. *Cornea* 2005;24:864–6.
 91. Yepes N, Lee SB, Hill V, et al. Infectious keratitis after overnight orthokeratology in Canada. *Cornea* 2005;24:857–60.
 92. Ying-Cheng L, Chao-Kung L, Ko-Hua C, Wen-Ming H. Daytime orthokeratology associated with infectious keratitis by multiple gram-negative bacilli: Burkholderia cepacia, Pseudomonas putida, and Pseudomonas aeruginosa. *Eye Contact Lens* 2006;32:19–20.
 93. Young AL, Leung AT, Cheng LL, et al. Orthokeratology lens-related corneal ulcers in children: a case series. *Ophthalmology* 2004;111:590–5.
 94. Young AL, Leung AT, Cheung EY, et al. Orthokeratology lens-related Pseudomonas aeruginosa infectious keratitis. *Cornea* 2003;22:265–6.
 95. Xuguang S, Lin C, Yan Z, et al. Acanthamoeba keratitis as a complication of orthokeratology. *Am J Ophthalmol* 2003;136:1159–61.
 96. Brand RJ, Polse KA, Schwalbe JS. The Berkeley Orthokeratology Study, Part I: general conduct of the study. *Am J Optom Physiol Opt* 1983;60:175–86.
 97. Polse KA, Brand RJ, Vastine DW, Schwalbe JS. Corneal change accompanying orthokeratology. Plastic or elastic? Results of a randomized controlled clinical trial. *Arch Ophthalmol* 1983;101:1873–8.
 98. Rued TC, Brungardt TF. Exotropia and orthokeratology: a case report. *J Am Optom Assoc* 1984;55:30, 42.
 99. Cavanagh HD. Orthokeratology: old devil vs. new saint: the dialogue continues. *Eye Contact Lens* 2004;30:179.
 100. Cavanagh HD. Orthokeratology: old devil or new saint? *Eye Contact Lens* 2004;30:119.
 101. Grant SC. Orthokeratology. I. A safe and effective treatment for a disabling problem. *Surv Ophthalmol* 1980;24:291–7.
 102. Kohnen T. Overnight orthokeratology induces irregular corneal astigmatism. *J Cataract Refract Surg* 2004;30:1389.
 103. Lui WO, Edwards MH, Cho P. Contact lenses in myopia reduction—from orthofocus to accelerated orthokeratology. *Cont Lens Anterior Eye* 2000;23:68–76.
 104. Safir A. Orthokeratology. II. A risky and unpredictable ‘treatment’ for a benign condition. *Surv Ophthalmol* 1980;24:291, 298–302.
 105. Saviola JF. The current FDA view on overnight orthokeratology: how we got here and where we are going. *Cornea* 2005;24:770–1.
 106. Schein OD. Microbial keratitis associated with overnight orthokeratology: what we need to know. *Cornea* 2005;24:767–9.
 107. Watt K, Swarbrick HA. Microbial keratitis in overnight orthokeratology: review of the first 50 cases. *Eye Contact Lens* 2005;31:201–8.
 108. Cho P, White P, Cheung SW. Orthokeratology lens-related ulcers in children [letter]. *Ophthalmology* 2005;112:167–8.
 109. Young AL, Fan DS, Lam DS, Qiu JK. In reply to: Cho P, White P, Cheung SW. Orthokeratology lens-related ulcers in children [letter]. *Ophthalmology* 2005;112:168–9.
 110. DeWolfson BH. Orthokeratology lens-related ulcers in children [letter]. *Ophthalmology* 2005;112:167.
 111. Young AL, Fan DS, Rao SK, Lam DS. In reply to: DeWolfson BH. Orthokeratology lens-related ulcers in children [letter]. *Ophthalmology* 2005;112:167.
 112. Boost MV, Cho P. Microbial flora of tears of orthokeratology patients, and microbial contamination of contact lenses and contact lens accessories. *Optom Vis Sci* 2005;82:451–8.
 113. Sridharan R, Swarbrick H. Corneal response to short-term orthokeratology lens wear. *Optom Vis Sci* 2003;80:200–6.
 114. Asbell PA. Corneal refractive therapy and the corneal surface. *Eye Contact Lens* 2004;30:236–7; discussion 242–3.
 115. Ladage PM, Yamamoto N, Robertson DM, et al. Pseudomonas aeruginosa corneal binding after 24-hour orthokeratology lens wear. *Eye Contact Lens* 2004;30:173–8.
 116. Dumbleton KA, Chalmers RL, Richter DB, Fonn D. Changes in myopic refractive error with nine months’ extended wear of hydrogel lenses with high and low oxygen permeability. *Optom Vis Sci* 1999;76:845–9.
 117. Efron N, Perez-Gomez I, Morgan PB. Confocal microscopic observations of stromal keratocytes during extended contact lens wear. *Clin Exp Optom* 2002;85:156–60.
 118. Golder S, McIntosh HM, Duffy S, Glanville J. Developing efficient search strategies to identify reports of adverse effects in MEDLINE and EMBASE. *Health Info Libr J* 2006;23:3–12.
 119. Lipson MJ. Long-term clinical outcomes for overnight corneal reshaping in children and adults. *Eye Contact Lens* 2008;34:94–9.
 120. Ren DH, Yamamoto K, Ladage PM, et al. Adaptive effects of 30-night wear of hyper-O(2) transmissible contact lenses on bacterial binding and corneal epithelium: a 1-year clinical trial. *Ophthalmology* 2002;109:27–39; discussion 39–40.

121. Bron AJ. Superficial fibrillary lines: a feature of the normal cornea. *Br J Ophthalmol* 1975;59:133–5.
122. Robertson DM, McCulley JP, Cavanagh HD. Severe Acanthamoeba keratitis after overnight orthokeratology. *Eye Contact Lens* 2007;33:121–3.
123. Alizadeh H, Apte S, El-Agha MS, et al. Tear IgA and serum IgG antibodies against Acanthamoeba in patients with Acanthamoeba keratitis. *Cornea* 2001;20:622–7.
124. Watt KG, Swarbrick HA. Trends in microbial keratitis associated with orthokeratology. *Eye Contact Lens* 2007; 33:373–7; discussion 382.
125. American Academy of Ophthalmology Refractive Management/Intervention Panel. Preferred Practice Pattern. Refractive Errors & Refractive Surgery. San Francisco, CA: American Academy of Ophthalmology; 2007:7–8. Available at: <http://one.aaopt.org/CE/PracticeGuidelines/PPP.aspx>. Accessed May 22, 2008.

Footnotes and Financial Disclosures

Originally received: June 4, 2008.

Accepted: June 26, 2008.

Manuscript no. 2008-685.

Financial Disclosure(s):

Financial disclosures of the authors are listed separately in Appendix 1 (available at <http://aaoptjournal.org>).

Funded without commercial support by the American Academy of Ophthalmology.

Prepared by the Ophthalmic Technology Assessment Committee Cornea and Anterior Segment Disorders Panel and approved by the American Academy of Ophthalmology's Board of Trustees April 11, 2008.

Appendix: Prepared by the Ophthalmic Technology Assessment Committee Cornea and Anterior Segment Disorders Panel and Approved by the American Academy of Ophthalmology's Board of Trustees April 11, 2008.

Financial disclosures of the authors for the years 2006 to 2008 are as follows.

| | | |
|-----------------------------|---|--|
| Woodford S. Van Meter, MD | N | |
| David C. Musch, PhD, MPH | C | Acuity Pharmaceuticals, AqueSys, Inc., Bausch & Lomb, Inc., Glaukos Corporation, IRIDEX, MacuSight, Inc., NeoVista, Inc., Neurotech USA, Inc., OPKO Health, Inc., XTL Biopharmaceuticals |
| | S | Midwest EyeBanks, National Eye Institute |
| Deborah S. Jacobs, MD | E | The Boston Foundation for Sight 501(c)3 |
| Stephen C. Kaufman, MD, PhD | C | Allergan, Inc. |
| William J. Reinhart, MD | L | Alcon Laboratories, Inc., Allergan, Inc. |
| Ira J. Udell, MD | N | |
| | C | Alcon Laboratories, Inc., InSite Vision, Inc., Vistakon |

| Code | Category | Specific Financial Relationship |
|------|--------------------|---|
| C | Consultant/Advisor | Consultant fee, paid advisory boards or fees for attending a meeting. |
| E | Employee | Employed by a commercial entity. |
| L | Lecture Fees | Lecture fees (honoraria), travel fees or reimbursements when speaking at the invitation of a commercial entity. |
| O | Equity Owner | Equity ownership/stock options of publicly or privately traded firms (excluding mutual funds) with manufacturers of commercial ophthalmic products or commercial ophthalmic services. |
| P | Patents/Royalty | Patents and/or royalties that might be viewed as creating a potential conflict of interest. |
| S | Grant Support | Grant support. |
| N | None | No financial interest. May be stated when such interests might falsely be suspected. |